Literature DB >> 26501695

Effect of ICD Therapies on Mortality in the OMNI Trial.

Shining Sun1, James Johnson2, Paul Degroot2, Mark L Brown2, Owen Obel1,3.   

Abstract

BACKGROUND: Analyses from primary prevention trials on implantable cardioverter defibrillator (ICD) therapy have shown an association between shocks and increased mortality. Recent data suggest a similar association with antitachycardia pacing (ATP).
OBJECTIVE: The OMNI study is an observational study of pacemaker and ICD use. We aim to examine associations between ICD therapies and mortality in this setting.
METHODS: A total of 2,255 OMNI patients with ICDs were included. Treated episodes were classified as appropriate or inappropriate. Patients were assigned into 1 of 3 groups depending on whether the episode required ATP only, single shock, or multiple shocks, and then followed for all-cause mortality. Additionally, we aimed to determine the frequency with which inappropriate ATP precipitated ventricular arrhythmias that led to shock, since this has been suggested as a mechanism of harm.
RESULTS: Over a mean follow-up of 39 ± 19 months, there were a total of 470 deaths (21%). Compared to patients with no treated episodes, patients with appropriate therapy had greater risk of death. Hazard ratios were 1.46 (95% confidence interval [CI] 1.05-2.02; P = 0.023) for the ATP-only group, 2.11 (95% CI 1.51-2.96; P < 0.001) for the single-shock group, and 2.55 (95% CI 1.43-4.57; P = 0.002) for the multishock group. There was no significant association between any type of inappropriate therapy and increased mortality. We identified only 7 instances of inappropriate ATP precipitating ventricular arrhythmia resulting in shock.
CONCLUSIONS: Patients receiving appropriate therapy of all types had increased mortality compared to those with no episodes. Furthermore, inappropriate ATP rarely precipitates ventricular arrhythmias.
© 2015 Wiley Periodicals, Inc.

Entities:  

Keywords:  ICD therapy; OMNI trial; antitachycardia pacing; implantable cardioverter defibrillator; mortality

Mesh:

Year:  2015        PMID: 26501695     DOI: 10.1111/jce.12860

Source DB:  PubMed          Journal:  J Cardiovasc Electrophysiol        ISSN: 1045-3873


  4 in total

1.  The Significance of Shocks in Implantable Cardioverter Defibrillator Recipients.

Authors:  Anthony Li; Amit Kaura; Nicholas Sunderland; Paramdeep S Dhillon; Paul A Scott
Journal:  Arrhythm Electrophysiol Rev       Date:  2016-08

2.  Ventricular Arrhythmia Burden as a Marker of Success Following Catheter Ablation of Ventricular Arrhythmias in Patients with Structural Heart Disease.

Authors:  Richard Bennett; Samual Turnbull; Yasuhito Kotake; Timothy Campbell; Saurabh Kumar
Journal:  Korean Circ J       Date:  2021-02-19       Impact factor: 3.243

3.  Mortality Implications of Appropriate Implantable Cardioverter Defibrillator Therapy in Secondary Prevention Patients: Contrasting Mortality in Primary Prevention Patients From a Prospective Population-Based Registry.

Authors:  Fahad Almehmadi; Andreu Porta-Sánchez; Andrew C T Ha; Hadas D Fischer; Xuesong Wang; Peter C Austin; Douglas S Lee; Kumaraswamy Nanthakumar
Journal:  J Am Heart Assoc       Date:  2017-08-19       Impact factor: 5.501

4.  Myocardial Minimal Damage After Rapid Ventricular Pacing - the prospective randomized multicentre MyDate-Trial.

Authors:  Verena Semmler; Clara Deutschmann; Bernhard Haller; Carsten Lennerz; Amir Brkic; Christian Grebmer; Patrick Blazek; Severin Weigand; Martin Karch; Sonia Busch; Christof Kolb
Journal:  Sci Rep       Date:  2020-03-16       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.